Trillium Therapeutics Inc. (TRIL) Receives Consensus Recommendation of “Buy” from Analysts
Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) has been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the stock. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $24.25.
A number of research analysts have issued reports on the company. Zacks Investment Research cut Trillium Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 9th. Cowen and Company reissued a “buy” rating on shares of Trillium Therapeutics in a research note on Monday, December 5th. Bloom Burton reissued a “buy” rating on shares of Trillium Therapeutics in a research note on Friday, November 4th. Finally, Leerink Swann reissued an “outperform” rating and issued a $20.00 target price on shares of Trillium Therapeutics in a research note on Thursday, November 3rd.
Shares of Trillium Therapeutics (NASDAQ:TRIL) traded down 2.22% on Friday, reaching $6.60. The company’s stock had a trading volume of 98,172 shares. The firm’s market cap is $51.59 million. The company’s 50 day moving average is $5.58 and its 200-day moving average is $9.84. Trillium Therapeutics has a 1-year low of $4.50 and a 1-year high of $17.70.
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/02/17/trillium-therapeutics-inc-tril-receives-consensus-recommendation-of-buy-from-analysts.html
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. New Leaf Venture Partners L.L.C. acquired a new position in Trillium Therapeutics during the fourth quarter worth about $547,000. Janus Capital Management LLC boosted its position in Trillium Therapeutics by 0.3% in the fourth quarter. Janus Capital Management LLC now owns 571,203 shares of the company’s stock worth $3,227,000 after buying an additional 1,619 shares during the last quarter. Oxford Asset Management boosted its position in Trillium Therapeutics by 47.7% in the fourth quarter. Oxford Asset Management now owns 24,660 shares of the company’s stock worth $139,000 after buying an additional 7,967 shares during the last quarter. Baker BROS. Advisors LP acquired a new position in Trillium Therapeutics during the third quarter worth about $6,120,000. Finally, Susquehanna International Group LLP acquired a new position in Trillium Therapeutics during the third quarter worth about $372,000. 42.78% of the stock is owned by hedge funds and other institutional investors.
This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/02/17/trillium-therapeutics-inc-tril-receives-consensus-recommendation-of-buy-from-analysts.html.
Trillium Therapeutics Company Profile
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.